

Reference Data

Contributing to building a sustainable society (External Evaluation)





December 14, 2022 press release

- •Non-profit CDP: Widely recognized as the global standard in corporate environmental information disclosures
- •This year, Nikon was again selected for the highest rank "A List" by the CDP's climate change questionnaire for the fourth consecutive year selected from FY2019

Member of

Dow Jones Sustainability Indices

Powered by the S&P Global CSA

December 13, 2022 press release

•A global ESG (Environment, Social and Governance) investment index

- •Nikon has been selected for the DJSI World and DJSI Asia Pacific Indices for the fifth consecutive year
- Nikon received the global top score in the industrial group*

*Industrial group as defined by S&P Global. LEG Leisure Equipment & Products and Consumer Electronics

,	Daw Janes	Custoinaluties		ESG ii	nvestment by	y GPIF: Included in all 5 indexes			
CDP Climate Change (UK)	Dow Jones Sustainability Indices (DJSI) (Switzerland, US) World	Sustainalytics (Netherlands) ESG risk score (Low risk: 20.0 or lower)	MSCI ESG Ratings (US)	lanan Indox	FTSE Blossom Japan Sector Relative Index	ESG Select	MSCI Japan Empowering Women Index (WIN)	S&P/JPX Carbon Efficient Index	
Α	In	15.6	AA	In	In	In	In	In	

Meet society's expectations to win "Trust"

Contribute to society through "Creativity"

Our corporate philosophy "Trustworthiness and Creativity"

Business segments and major products



Segments	Description	Major products
Imaging Products Business	Digital camera-interchangeable lens type Interchangeable lens Compact DSC	Mirrorless Camera [Z 9] Mirrorless Camera [Z 30] Mirrorless Camera [Z 30] Mirrorless Camera [Z 30] Mirrorless Camera [Z 30]
Precision Equipment Business	FPD lithography system Semiconductor lithography system Alignment Station Measuring & inspection systems	FPD Scanner [FX-88S] ArF Immersion Scanner [NSR-5635E] Alignment Station [Litho Booster] Automatic Macro Inspection System [AMI-5700]
Healthcare Business	Biological microscope Retinal diagnostic imaging system Contract Cell Manufacturing business	Confocal Microscope System [AX/AX R] Ultra-Widefield Retinal Diagnostic Imaging System with Integrated UWF-Guided Swept Source OCT [Silverstone.] Contract Cell Manufacturing
Components Business	EUV related component Optical components, Optical parts Encoders and Actuators Photomask substrate for FPD Optical processing machine and Contract material processing	Optical Processing Machine [C3 eMotion] Optical Components Optical Frocessing Machine [Lasermeister102A]
Industrial Metrology and Others	Measuring instrument X-ray system Industrial microscopy	Video Measuring System [NEXIV VMZ-S Series] Video Measuring System [NEXIV VMZ-S Series] X-Ray and CT Systems [XT H 225 ST 2x] Laser Radar Measuring System [APDIS]

3rd quarter of the year ending March 31, 2023: Financial Highlights



Billions of Yen	FY2022/3 Q3 Actual (A)	FY2023/3 Q3 Actual (B)	Cha Amount (B)-(A)	nge % (B)/(A)
Revenue	133.3	167.7	+34.4	+25.9%
Operating profit % vs Revenue	14.8 11.1%	26.2 15.6%	+11.4	+76.5%
Profit before tax % vs Revenue	16.6 12.5%	26.3 15.7%	+9.7	+57.9%
Profit attributable to owners of parent % vs Revenue	12.6 9.5%	20.6 12.3%	+8.0	+63.2%
FCF	3.6	-3.4	-7.0	-
Exchange Rate : US\$	¥114	¥141	·	n Revenue 5.1
EURO	¥130	¥144		perating profit 3.2

Increased in revenue and operating profit YoY

3rd quarter of the year ending March 31, 2023: Performance by Segment



		FY2022/3 Q3	FY2023/3 Q3	Ch	ange
Billions of Yen	_	Actual (A)	Actual (B)	Amount (B)-(A)	% (B)/(A)
Imaging Products	Revenue	46.8	69.9	+23.1	+49.4%
Business	Operating profit	6.3	19.0	+12.7	+204.7%
Precision Equipment	Revenue	43.7	50.2	+6.5	+14.8%
Business	Operating profit	5.9	8.4	+2.5	+40.7%
Healthcare Business	Revenue	20.2	25.5	+5.3	+26.6%
neallicare business	Operating profit	1.9	3.6	+1.7	+91.2%
Components Business	Revenue	13.9	12.1	-1.8	-13.0%
Components Business	Operating profit	6.7	3.5	-3.2	-46.1%
Industrial Metrology	Revenue	8.9	10.2	+1.3	+15.1%
and Others	Operating profit	1.7	0.9	-0.8	-48.1%
Corporate P/L non- attributable to any reportable segments	Operating profit	-7.7	-9.2	-1.5	-
Concolidated	Revenue	133.3	167.7	+34.4	+25.9%
Consolidated	Operating profit	14.8	26.2	+11.4	+76.5%

Corporate P/L non-attributable to any reportable segments down on booking of costs related to SLM acquisition and increased R&D costs

Note: From FY2023/3, the "Next Generation Project Div." is transferred from the Precision Equipment Business to Corporate P/L non-attributable to any reportable segments, and retroactively applied to FY2022/3. Corporate P/L non-attributable to any reportable segments includes the elimination of intersegment transactions.

The amount of the elimination of intersegment transactions: ¥3.2B in FY2022/3 Q3, ¥3.3B in FY2023/3 Q3

Forecast for the year ending March 31, 2023: Financial Highlights



	FY2020/3	FY2021/3	FY2022/3			FY20)23/3 (fore	cast)
Billions of Yen	Full Year	Full Year	1H	2H	Full Year	1H	2H	Full Year
Revenue	591.0	451.2	273.0	266.6	539.6	288.3	341.7	630.0
Operating profit % vs Revenue	6.7 1.1%	-56.2 -12.5%	32.1 11.8%	17.8 6.7%	49.9 9.3%	24.4 8.5%	30.6 9.0%	55.0 8.7%
Profit before tax	11.8	-45.3	35.9	21.1	57.0	26.0	31.0	57.0
% vs Revenue	2.0%	-10.0%	13.2%	7.9%	10.6%	9.0%	9.1%	9.0%
Profit attributable to owners of parent	7.6	-34.4	26.4	16.2	42.6	18.8	23.2	42.0
% vs Revenue	1.3%	-7.6%	9.7%	6.1%	7.9%	6.5%	6.8%	6.7%
EPS	¥19.93	-¥93.96		¥116.23			¥116.71	
Annual Dividends	¥40	¥20		¥40			¥40	
ROE	1.3%	-6.4%		7.5%			7.0%	
FCF	-4.8	22.9		30.9			-	
Exchange Rate : US\$ EURO	¥109 ¥121	¥106 ¥124	¥110 ¥131	¥115 ¥130	¥112 ¥131	¥134 ¥139	¥136 ¥140	¥135 ¥139

Forecast for the year ending March 31, 2023: Financial Highlights (Changes from Previous Forecast)



	Previous Forecast (Nov. 10) (A)				New Forecast (Feb. 9) (B)			Change (B)-(A)		
Billions of Yen	1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year	
Revenue	288.3	356.7	645.0	288.3	341.7	630.0	±0.0	-15.0	-15.0	
Operating profit % vs Revenue	24.4 8.5%	30.6 8.6%	55.0 8.5%	24.4 8.5%	30.6 9.0%	55.0 8.7%	±0.0	±0.0	±0.0	
Profit before tax	26.0	31.0	57.0	26.0	31.0	57.0	±0.0	±0.0	±0.0	
% vs Revenue	9.0%	8.7%	8.8%	9.0%	9.1%	9.0%				
Profit attributable to owners of parent	18.8	23.2	42.0	18.8	23.2	42.0	±0.0	±0.0	±0.0	
% vs Revenue	6.5%	6.5%	6.5%	6.5%	6.8%	6.7%				
EPS		¥115.63			¥116.71			+¥1.08		
Annual Dividends		¥40			¥40			±¥0		
ROE		6.9%			7.0%			+0.1P		
Exchange Rate : US\$ EURO	¥134 ¥139	¥135 ¥135	¥135 ¥137	¥134 ¥139	¥136 ¥140	¥135 ¥139	±¥0	+¥1 +¥5	±¥0 +¥2	

Forecast for the year ending March 31, 2023: Forecast by Segment



			FY2022/3	3	FY20	23/3 (fore	cast)
Billions of Yen		1H	2H	Full Year	1H	2H	Full Year
Imaging Products	Revenue	89.2	89.0	178.2	114.5	115.5	230.0
Business	Operating profit	12.5	6.5	19.0	22.2	19.8	42.0
Precision Equipment	Revenue	119.2	92.0	211.2	83.3	126.7	210.0
Business	Operating profit	27.5	11.9	39.4	6.2	17.8	24.0
Healthcare Business	Revenue	33.0	40.2	73.2	46.6	46.4	93.0
Healthcare Busilless	Operating profit	0.9	3.4	4.3	3.6	4.4	8.0
Components Business	Revenue	16.7	24.1	40.8	26.0	27.0	53.0
Components Business	Operating profit	3.4	9.3	12.7	9.8	8.2	18.0
Industrial Metrology	Revenue	14.6	21.4	36.0	17.6	26.4	44.0
and Others	Operating profit	-1.6	4.5	2.9	1.5	2.0	3.5
	Operating profit	-10.7	-17.9	-28.6	-19.1	-21.4	-40.5
Corporate P/L non-attributable	Broken out: Expense related to investment in growth	-10.4	-11.4	-21.8	-10.8	-12.2	-23.0
to any reportable segments	Broken out: Expense for administration department		-5.8	-8.0	-7.0	-8.5	-15.5
Consolidated	Revenue	273.0	266.6	539.6	288.3	341.7	630.0
Consolidated	Operating profit	32.1	17.8	49.9	24.4	30.6	55.0

Note: From FY2023/3, the "Next Generation Project Div." is transferred from the Precision Equipment Business to Corporate P/L non-attributable to any reportable segments (Expense related to investment in growth), and retroactively applied to FY2022/3.

[&]quot;Expense related to investment in growth" is expenses mainly related to basic research, expense related to the creation of new businesses, and expense related to manufacturing innovation.

[&]quot;Expense for administration department" is general administrative expenses for head office functions, and corporate P/L non-attributable to any reportable segments. Corporate P/L non-attributable to any reportable segments includes the elimination of intersegment transactions.

Forecast for the year ending March 31, 2023: Forecast by Segment (Changes form Previous Forecast)



		Previous Forecast (Nov. 10) (A)		New Forecast (Feb. 9) (B)		Change (B)-(A)				
Billions of Yen		1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
Imaging Products	Revenue	114.5	115.5	230.0	114.5	115.5	230.0	±0.0	±0.0	±0.0
Business	Operating profit	22.2	10.8	33.0	22.2	19.8	42.0	±0.0	+9.0	+9.0
Precision Equipment	Revenue	83.3	146.7	230.0	83.3	126.7	210.0	±0.0	-20.0	-20.0
Business	Operating profit	6.2	23.8	30.0	6.2	17.8	24.0	±0.0	-6.0	-6.0
Hooltheave Dusiness	Revenue	46.6	46.4	93.0	46.6	46.4	93.0	±0.0	±0.0	±0.0
Healthcare Business	Operating profit	3.6	4.4	8.0	3.6	4.4	8.0	±0.0	±0.0	±0.0
Componente Business	Revenue	26.0	27.0	53.0	26.0	27.0	53.0	±0.0	±0.0	±0.0
Components Business	Operating profit	9.8	8.2	18.0	9.8	8.2	18.0	±0.0	±0.0	±0.0
Industrial Metrology	Revenue	17.6	21.4	39.0	17.6	26.4	44.0	±0.0	+5.0	+5.0
and Others	Operating profit	1.5	3.0	4.5	1.5	2.0	3.5	±0.0	-1.0	-1.0
Corporate P/L non-attributable to any reportable segments	Operating profit	-19.1	-19.4	-38.5	-19.1	-21.4	-40.5	±0.0	-2.0	-2.0
Canadidated	Revenue	288.3	356.7	645.0	288.3	341.7	630.0	±0.0	-15.0	-15.0
Consolidated	Operating profit	24.4	30.6	55.0	24.4	30.6	55.0	±0.0	±0.0	±0.0

Note: Corporate P/L non-attributable to any reportable segments includes the elimination of intersegment transactions.

3rd quarter of the year ending March 31, 2023: Quarterly Performance by Segment



	l l		FY20	22/3			FY2023/3	
Billions of Yen		Q1	Q2	Q3	Q4	Q1	Q2	Q3
Imaging Products	Revenue	50.0	39.2	46.8	42.2	61.2	53.3	69.9
Business	Operating profit	9.2	3.3	6.3	0.2	13.6	8.6	19.0
Precision Equipment	Revenue	51.8	67.4	43.7	48.3	41.4	41.9	50.2
Business	Operating profit	13.4	14.1	5.9	6.0	4.0	2.2	8.4
Hooltheare Pusiness	Revenue	15.8	17.2	20.2	20.0	21.7	24.9	25.5
Healthcare Business	Operating profit	0.4	0.5	1.9	1.5	0.8	2.8	3.6
Components Business	Revenue	7.7	9.0	13.9	10.2	12.9	13.1	12.1
Components Business	Operating profit	2.1	1.3	6.7	2.6	5.4	4.4	3.5
Industrial Metrology	Revenue	6.7	7.9	8.9	12.5	8.1	9.5	10.2
and Others	Operating profit	-1.0	-0.6	1.7	2.8	0.6	0.9	0.9
	Operating profit	-4.3	-6.4	-7.7	-10.2	-9.2	-9.9	-9.2
Corporate P/L non-attributable to	Broken out: Expense related to investment in growth	-5.0	-5.4	-5.3	-6.1	-5.3	-5.4	-6.0
any reportable segments	Broken out: Expense for administration department	0.1	-2.3	-2.7	-3.1	-2.7	-4.2	-3.5
Consolidated	Revenue	132.2	140.8	133.3	133.3	145.6	142.7	167.7
Consolidated	Operating profit	19.9	12.2	14.8	3.0	15.3	9.1	26.2


Note: From FY2023/3, the "Next Generation Project Div." is transferred from the Precision Equipment Business to Corporate P/L non-attributable to any reportable segments (Expense related to investment in growth), and retroactively applied to FY2022/3.

[&]quot;Expense related to investment in growth" is expenses mainly related to basic research, expense related to the creation of new businesses, and expense related to manufacturing innovation. "Expense for administration department" is the general administrative expenses for head office functions, and corporate P/L non-attributable to any reportable segments.


Corporate P/L non-attributable to any reportable segments includes the elimination of intersegment transactions.

3rd quarter of the year ending March 31, 2023: Financial Position





LIABILITIES/ EQUITY




Note: Equity ratio is the ratio of equity attributable to owners of parent to total assets.


Cash and cash equivalents excludes time deposits with maturities of three months or more.

Forecast for the year ending March 31, 2023: Capital Expenditures, Depreciation & Amortization, and Inventories Nikon

CAPITAL EXPENDITURES, DEPRECIATION & AMORTIZATION




BREAKDOWN OF INVENTORIES



Note: Capital expenditures in FY2020/3 and later include the leased assets upon the adoption of IFRS16.

1st to 3rd quarters of the year ending March 31, 2023: Revenue Breakdown







Forecast for the year ending March 31, 2023: R&D Expenditures



R&D EXPENDITURES



R&D EXPENDITURES BREAKDOWN




Note: R&D expenditures includes capitalization of some development expenditures.

Due to segment revision from FY2023/3, the financial figures for FY2022/3 are displayed according to the reorganized display.

Cash Flow History






Note: FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents

Imaging Products Business: Sales Units








Note: Compact DSC: A camera equipped with integrated lens and do not have the function to replace lenses. (Eligible products of Nikon: COOLPIX P1000, P950, etc.)

Forecast for the year ending March 31, 2023: Precision Equipment Business Sales Units



FPD LITHOGRAPHY SYSTEMS SALES BY GENERATION

SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES BY TECHNOLOGY (INCL. REFURBISHED)




Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of the "Mini Step & Repeat Exposure System".

The unit sales of new semiconductor lithography systems are 27 units in FY2019/3, 38 units in FY2020/3, 23 units in FY2021/3, 17 units in FY2022/3, and 28 units (forecast) in FY2023/3.

Precision Equipment Business: Sales Units






Precision Equipment Business: Sales Units







Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of the "Mini Step & Repeat Exposure System".

Forecast for the year ending March 31, 2023: Foreign Exchange Impact



	Exchange Rate	Financial Impact from Fluctuation by 1 yer				
	FY2023/3 Forecast for Q4	Revenue Q4	Operating Profit Q4			
US \$	¥130	Approx. ¥0.5billion	Approx. ¥0.1billion			
EURO	¥135	Approx. ¥0.2billion	Approx. ¥0.1billion			

Note: The foreign exchange impact above is made on the assumption that emerging-market currencies move according to the influence of US\$ and Euro.

Disclaimer Regarding Forecast and Projections



Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.

